Finance

Lists
SNDX:NASDAQ
Syndax Pharmaceuticals Inc
$17.86
-1.87%
(-0.34) 1D
$18.08
+1.23% (+0.22)
After hours
Closed: Sep 28, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SNDX...
Open
$18.16
High
$18.16
Low
$17.60
Mkt. cap
1.59B
Avg. vol.
1.58M
Volume
1.55M
52-wk high
$25.59
52-wk low
$12.99
EPS
-$2.52
Beta
0.37
Shares outstanding
89.30M
No. of employees
298
Open
$18.16
High
$18.16
Low
$17.60
Mkt. cap
1.59B
Avg. vol.
1.58M
Volume
1.55M
52-wk high
$25.59
52-wk low
$12.99
EPS
-$2.52
Beta
0.37
Shares outstanding
89.30M
No. of employees
298
News stories
From web sources and news partners
About Syndax Pharmaceuticals Inc
CEO-
Employees298
Founded2005
Headquarters-
SectorBiotechnology
Websitesyndax.com
Analyst ratings
Based on 10 analysts giving stock ratings to SNDX in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for SNDX in the last 3 months.
Highest
Current $17.86
$57.00 (+219.15%)
Average
$37.33 (+109.01%)
Lowest
$26.00 (+45.58%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$38.00
+112.8%
09/21/2026
David Dai
UBS
Buy
Reiterated
$33.00
+84.8%
08/21/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$40.00
+124%
08/14/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$40.00
+124%
08/11/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$26.00
+45.6%
08/05/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$57.00
+219.1%
08/05/2026
Etzer Darout
Barclays
Buy
Maintained
$37.00
+107.2%
08/05/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/04/2026
Bradley Canino
Guggenheim
Buy
Maintained
$31.00
+73.6%
07/14/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$34.00
+90.4%
07/14/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$37.00
+107.2%
05/01/2026
Unknown Analyst
Jefferies
Buy
Maintained
$40.00
+124%
03/30/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$43.00
+140.8%
03/30/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$43.00
+140.8%
03/30/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.55 / -$0.44
-26.01%miss
Revenue / Est. (USD)
72.79M / 79.56M
-8.51%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
45.87M
68.73M
64.86M
72.79M
Cost of goods sold
58.38M
81.35M
61.48M
71.24M
Cost of revenue
58.38M
81.35M
61.48M
71.24M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
44.92M
49.93M
37.59M
41.54M
Operating expense
44.92M
49.93M
37.59M
41.54M
Total operating expenses
103.30M
131.28M
99.07M
112.78M
Operating income
-57.43M
-62.55M
-34.20M
-40.00M
Other non operating income
-275.00K
-201.00K
-186.00K
-438.00K
EBT including unusual items
-60.72M
-68.01M
-42.67M
-49.36M
EBT excluding unusual items
-60.72M
-68.01M
-42.67M
-49.36M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-60.72M
-68.01M
-42.67M
-49.36M
Net profit margin
-132.36%
-98.96%
-65.79%
-67.82%
Earnings per share
-0.70
-0.78
-0.48
-0.55
Interest and investment income
5.27M
4.33M
3.56M
3.75M
Interest expense
-8.28M
-9.59M
-11.85M
-12.68M
Net interest expenses
-3.01M
-5.26M
-8.28M
-8.93M
Depreciation and amortization charges
-
-
-
-
EBITDA
-57.42M
-62.54M
-34.20M
-39.99M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps